TY - JOUR
T1 - New and emerging therapies for paediatric atopic dermatitis
AU - Vakharia, Paras P.
AU - Silverberg, Jonathan I.
N1 - Funding Information:
JIS reports personal fees from Abbvie, Anaptysbio, Asana, Eli Lilly, Galderma, GlaxoSmithKline, Kiniksa, Leo, Menlo, Pfizer, Realm, Regeneron-Sanofi, and Roivant, and grants from GlaxoSmithKline, Regeneron-Sanofi, and Galderma, during the conduct of the Review. JIS is supported by a grant from the Dermatology Foundation, Evanston, IL, USA. PPV declares no competing interests. The funding source had no involvement in design or conduct of the Review, in collection, management, analysis or interpretation of data, in preparation, review, or approval of the manuscript, or in the decision to submit the manuscript for publication.
Publisher Copyright:
© 2019 Elsevier Ltd
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/5
Y1 - 2019/5
N2 - Atopic dermatitis is a complex, chronic inflammatory skin disorder with a profound symptom burden, and substantially affects patients' quality of life. It is particularly challenging to manage in children, because conventional treatments such as topical corticosteroids might be inadequate or cause considerable safety concerns. Research into the pathogenesis of atopic dermatitis has led to the testing and development of numerous topical, oral, and injectable targeted therapeutic agents. This Review explores relevant drugs that hold therapeutic promise and are being studied in the paediatric setting, with a focus on target relevance, available efficacy and safety data, potential safety concerns, and long-term effect in children with atopic dermatitis.
AB - Atopic dermatitis is a complex, chronic inflammatory skin disorder with a profound symptom burden, and substantially affects patients' quality of life. It is particularly challenging to manage in children, because conventional treatments such as topical corticosteroids might be inadequate or cause considerable safety concerns. Research into the pathogenesis of atopic dermatitis has led to the testing and development of numerous topical, oral, and injectable targeted therapeutic agents. This Review explores relevant drugs that hold therapeutic promise and are being studied in the paediatric setting, with a focus on target relevance, available efficacy and safety data, potential safety concerns, and long-term effect in children with atopic dermatitis.
UR - http://www.scopus.com/inward/record.url?scp=85064081495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064081495&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(19)30030-6
DO - 10.1016/S2352-4642(19)30030-6
M3 - Review article
C2 - 30904349
AN - SCOPUS:85064081495
VL - 3
SP - 343
EP - 353
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
SN - 2352-4642
IS - 5
ER -